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We have previously reported, using tumor specimens resected following Bev therapy (under the Bev efficacy), that Bev induces the normalization of vascular structure, reduction of microvessel density, and improves tumor oxygenation. 4 In addition, by comparing tumors resected before treatment (initial tumor), following Bev therapy (under the Bev efficacy), and at the time of recurrence, tumor hypoxia was regained while the microvessel density was still paradoxically lowered in recurrent tumors after Bev therapy, suggesting that the re-activation of tumor angiogenesis might not be involved in the first stage of refractoriness to Bev.
5
Bevacizumab is known to enhance the effects of immunotherapy, because VEGF-A suppresses antitumor immunity by inhibiting the maturation of DCs and stimulating the proliferation of Tregs. 6, 7 Indeed, the combination of atezolizumab, the anti-PD-L1 antibody, and Bev induced a strong and synergistic antitumor effect on tumors with high levels of VEGF-A, by the induction of CTLs. 8, 9 This study aims to investigate the status and change of immunosuppressive cells and immune checkpoint molecules regarding
Bev usage. The analyses were carried out by immunohistochemistry using and comparing tumor specimens resected at 3 different settings: tumors before any treatment, tumors resected following Bev therapy (under the Bev efficacy), and recurrent tumors after Bev therapy. To the best of our knowledge, this is the first study to show the status of key molecules/cells in the tumor immune microenvironment regarding Bev therapy using actual human tumor specimens.
| MATERIAL S AND ME THODS

| Patients and tissues
The present study used 47 glioblastoma tissues from 31 patients obtained at 3 different settings: 15 tumors resected following Bev therapy (under the Bev efficacy, defined as the "effective Bev group"), 20
tumors of initial glioblastoma (defined as the "naïve Bev group"), and 12 post-Bev recurrent tumors (defined as the "refractory Bev group") ( Table S1 ). The 15 tumors resected following Bev therapy (cases [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] were the tumors resected after 1-3 times of the preoperative Bev administration at a dose of 10 mg/kg for a safer surgical resection or as a consequence of the clinical course, and included 3 tumors enrolled in the phase II study of neoadjuvant Bev (UMIN000025579). Tumor resection was carried out 21-36 days after the last Bev treatment.
Fourteen of the 15 patients (except case 1) were newly diagnosed cases. One patient (case 1) was treated with Bev at tumor recurrence, and resection was carried out under the Bev efficacy.
Six of the 15 patients in the effective Bev group had recurrent disease. Among these 6 patients, 2 underwent surgical resection F I G U R E 1 Patients and tissues. The present study used 47 glioblastoma tissues obtained from 3 different settings: 15 tumors resected under neoadjuvant bevacizumab (Bev) therapy (A; defined as the "effective Bev group"), 20 initial glioblastomas before treatment (B-D; defined as the "naïve Bev group"), and 12 recurrent tumors of post Bev therapy (A-C; defined as the "refractory Bev group"). The 15 patients in the effective Bev group (cases 1-15) were treated 1-3 times with preoperative Bev at a dose of 10 mg/kg, and resection was carried out 21-36 days after the last Bev treatment (A). In the refractory Bev group, 3 tumors were recurrent from 3 patients after neoadjuvant Bev therapy for newly diagnosed glioblastomas (A). In the naïve and refractory Bev groups, paired samples of pre-and post-Bev therapy were collected from 9 patients (B,C). RT, radiotherapy; TMZ, temozolomide for the recurrent tumor (cases 2 and 5), and autopsy tissue was obtained from 1 patient (case 3) ( Figure 1A In the naïve Bev group, the other 11 tumors included 10 consecutive newly diagnosed glioblastomas (all primary glioblastomas) and 1 secondary glioblastoma before neoadjuvant Bev therapy in case 1
(recurrence of anaplastic astrocytoma) ( Figure 1D ). 
| Immunohistochemical analyses
Histopathological analyses were undertaken on 4-μm sections of formalin-fixed, paraffin-embedded tissue of 47 tumors. All of the available tissue blocks were examined for each of the following analyses.
Standard immunohistochemistry was carried out. Sections were deparaffinized and rehydrated. The antigen retrieval was carried out in citrate buffer (pH 6 for PD-1, CD3, Foxp3, and CD163), or in Tris buffer (pH 9 for PD-L1 and CD8) using micro- For the assessment of PD-1, CD3, CD8, Foxp3, and CD163, the stained sections were screened at low-power field (×40), and 5 hot spots were selected. The number of positive cells in these areas were counted at HPF ×400, 0.47 mm 2 .
The expression of PD-L1 was scored as a percentage of tumor cells expressing PD-L1, as described previously (3+, ≥50%; 2+, ≥5% and <50%; 1+, ≥1% and <5%; and 0, <1%). were carried out with IBM SPSS statistics. P value <.05 was considered to be statistically significant.
| RE SULTS
Clinical characteristics and the results of immunohistochemical analyses of 47 tumors are summarized in Tables S1 and S2.
| Expression of PD-L1 and PD-1
The expression of PD-L1 was observed on the cell membrane and in the cytoplasm of tumor cells ( Figure 2A ). Endothelial cells were also occasionally stained. In the naïve Bev group, the PD-L1 score | 503 TAMURA eT Al.
| Expression of CD3 and CD8
The refractory Bev group showed a trend toward an increased number (Table S2 ).
| Expression of Foxp3
The number of Foxp3+ T cells, or Tregs, decreased in the effective or refractory Bev group compared with the naïve Bev group (naïve Bev group, 
| Expression of CD163
The 
| D ISCUSS I ON
The present study showed that, using human glioblastoma specimens [12] [13] [14] However, this is the first study to show the overall picture of the key molecules/cells in tumor immunity in relation to antiangiogenic therapy based on the evidence using human specimens. Furthermore, it is the first to reveal that the phenomenon sustains during long-term Bev therapy.
| Programmed cell death ligand-1/PD-1/CD3/ CD8/Tregs
Programmed cell death ligand-1 is frequently expressed in glioblastomas reportedly in 61%-88% of tumor cells. 15 Previous studies showed that high PD-L1 expression correlated with worse OS in patients with glioblastoma. 16 The expression of PD-L1 is induced by various pro-inflammatory molecules such as γ-interferon and VEGF-A in the tumor microenvironment. renal cell carcinoma through vascular normalization and endothelial cell activation. 8, 9 In the present study, tumor-infiltrating CD3 or CD8+ T cells numerically increased after Bev therapy, especially in tumors of the refractory Bev group, compared with the naïve Bev group.
Regulatory T cells produce transforming growth factor-β, IL-10, and granzyme B, which trigger the apoptosis of cytotoxic T cells. 
| Tumor-associated macrophages
Bone marrow-derived cells, including CD163+ TAMs, have been associated with tumor progression, angiogenesis, invasion, metastasis, and treatment evasion. 34, 35 Typically, CD163+ TAMs behave as M2 macrophages to suppress the host immune response.
36,37
Tumor-associated macrophages promote angiogenesis and invasion by various cytokines or growth factors, including basic fibroblast growth factor, MMP9, and VEGF-A. 35 In addition, a previous study involving autopsy specimens reported that CD163+ TAMs increased in the infiltrative edge of glioblastomas following antiangiogenic therapy comprising Bev and cediranib. 38 The present study revealed that the number of CD163+ TAMs in tumors of the effective and refractory Bev groups was significantly decreased compared with that in the naïve Bev group. We did not observe any difference in CD163+ cell density between the tumor bulk and infiltrative edge.
| Effect of continuous VEGF blockade vs recovery of hypoxia on infiltration of immunesuppressive cells
Hypoxia affects the tumor immune microenvironment by upregulation of VEGF-A via HIF-1α. 39 In addition, hypoxia is directly associated with immunosuppressive cells and molecules. 39 The conversion of naïve T cells into Tregs is controlled by the transcription factor Foxp3, which is upregulated in hypoxia through HIF-1. 40 The hypoxic condition also contributes to phenotypic control of macrophages into a specific M2 phenotype (TAM). 41 Hypoxiainducible factor-1α was also able to activate the expression of PD-L1 by binding of HIF to a specific hypoxic response element in the promoter of PD-L1 in cancer cells. 42, 43 We have previously reported that Bev improves tumor oxygenation in glioblastomas, 
| Limitations of the study
Some could argue that the tumors in the refractory Bev group were the recurrent tumors following not only Bev but also radiotherapy and temozolomide, and those therapies might also have affected the immunohistochemical results. However, the expression of PD-1 and PD-L1 was known to increase in recurrent glioblastomas, 16, 29 and the results contrary to those were very likely due to the effect of Bev.
Another limitation of the present study was the paucity of the number of paired tissues from the same patients because salvage surgery following Bev failure is extremely rare. Ideally, studies using a larger number of paired samples are warranted to confirm the findings of this study. 
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